GlobeNewswire·Nov 9, 2026, 9:00 AM ET

Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine

Part A of the Phase 2b TYDAL-TIMI 78 trial met all objectives, demonstrating statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three MAR001 doses at Week 12.
Participants with baseline triglycerides ≥300 mg/dL achieved placebo-adjusted reductions up to 57.2%, while those with baseline levels ≥500 mg/dL saw reductions from baseline up to 72.2%.
At the 900 mg dose, 51.7% of participants reached normal triglyceride levels (<150 mg/dL) at Week 12, compared to 3.4% on placebo.
MAR001 also produced significant placebo-adjusted reductions in remnant cholesterol ranging from 37.3% to 40.8% across the three doses at Week 12.
The drug exhibited a favorable safety profile with adverse event rates similar to placebo, no cases of pancreatitis, no deaths, and no worsening of HbA1c or glucose homeostasis markers.
Marea Therapeutics has initiated enrollment in Part B of the TYDAL-TIMI 78 trial, which will focus on approximately 100 participants with severe hypertriglyceridemia (sHTG).
Data from the trial were presented as a late-breaking clinical trial at the American Heart Association Scientific Sessions 2026 and published in The New England Journal of Medicine.
Lisata Therapeutics is advancing MAR005, a half-life-extended version of MAR001, as its planned Phase 3 candidate for the treatment of sHTG.